Breckenridge Pharmaceutical Launches Generic of Ambien CR
This is the eighth generic version of the drug to treat insomnia.
Breckenridge Pharmaceutical in Berlin, Conn., has launched zolpidem tartrate extended-release tablets, a generic version of Sanofi’s Ambien CR. The product is manufactured by Centaur Pharmaceuticals. Breckenridge, a subsidiary of Towa Pharmaceutical in Osaka, Japan, will market the product with its own label and offer 6.25 mg and 12.5 mg strengths in bottles of 100.
The FDA had granted final approval of this product’s abbreviated new drug application in June 2020. This is the eighth approval of generic for Ambien, according to Drugs.com.
Ambien CR and its generics had annual sales of $42 million during the 12 months ending May 2021, according to Breckenridge.
About 35% of adults have sleeping problems, according to CDC. People who sleep less than seven hours a night are more likely to have chronic health conditions than those who sleep seven or more hours a night, according to the CDC. These include heart attack, coronary heart disease, stroke, asthma, and chronic obstructive pulmonary disease.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
